Approval · Notice of Compliance 28773 · 2022
JADENU: Notice of Compliance 28773
Issued August 17, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28773
- Date
- August 17, 2022
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JADENU | Not yet assigned | — |
Medicinal ingredients
- DEFERASIROX 90 MG per MG
- DEFERASIROX 180 MG per MG
- DEFERASIROX 360 MG per MG